Thirty Madison: Which Patient Profiles Should Avoid Keeps, Cove, and Its Other Brands

What Is Thirty Madison and How Does Its Prescribing Model Work

Thirty Madison is a New York-based telehealth holding company that operates condition-specific sub-brands rather than a single general platform. Its best-known brands are Keeps (androgenetic alopecia), Cove (migraine), and Facet (dermatology). The company acquired Lemonaid Health in 2021, expanding into primary care and sexual health. Prescriptions are written by licensed physicians or nurse practitioners after patients complete an online intake questionnaire; not all pathways require a live video visit.

The Asynchronous Intake Problem

Most Thirty Madison pathways allow asynchronous prescribing. A patient fills out a form, uploads photos if relevant, and a clinician reviews the file at a later time. The FDA's 2023 telehealth prescribing guidance notes that synchronous evaluation is preferred when the clinical presentation could involve findings detectable only on physical examination [1]. Asynchronous models compress the time available for a clinician to ask follow-up questions, and the intake forms are not equivalent to a structured history and physical.

Drug Portfolio Overview

The drugs dispensed across Thirty Madison brands include finasteride (Keeps), dutasteride (Keeps), minoxidil oral and topical (Keeps), sumatriptan and topiramate (Cove), tretinoin and azelaic acid (Facet), and sildenafil or tadalafil (Lemonaid/Keeps sexual health). Each of these agents carries FDA-labeled contraindications and drug-interaction warnings that require accurate, complete medical histories to screen properly [2].

Patient Profiles Who Should Avoid Keeps (Hair Loss)

Keeps prescribes finasteride 1 mg orally, oral minoxidil, and topical minoxidil for male androgenetic alopecia. These are legitimate, evidence-based treatments. A 2018 systematic review in the Journal of the American Academy of Dermatology (N=1,879 participants across 22 trials) confirmed that oral finasteride significantly improves hair count compared with placebo (P<0.001) [3]. The issue is not drug efficacy. The issue is patient selection.

Patients With Prostate Cancer History or Elevated PSA

Finasteride suppresses dihydrotestosterone by inhibiting 5-alpha reductase. The Prostate Cancer Prevention Trial (N=18,882) demonstrated that finasteride use is associated with a 24.8% relative reduction in prostate cancer prevalence but also with a higher proportion of high-grade tumors (Gleason score 7 to 10) in the finasteride arm: 6.4% vs. 5.1% in placebo [4]. Any patient with a personal or first-degree family history of prostate cancer, or an unexplained PSA elevation, needs urologic evaluation before starting finasteride. Keeps' asynchronous intake cannot adequately assess this risk.

Patients With Hepatic Impairment

Finasteride is hepatically metabolized. The FDA prescribing label for finasteride (Propecia) states that pharmacokinetics have not been studied in patients with hepatic insufficiency and cautions against use in this population [2]. Keeps' intake questionnaire does not perform liver function screening.

People Who Are Pregnant or Could Become Pregnant

The FDA classifies finasteride as Pregnancy Category X (now Avoid Use per current labeling). Exposure in pregnant women carrying a male fetus causes abnormalities of the external genitalia [2]. Keeps markets to men, but the risk to household contacts who are pregnant is real. This is not merely a theoretical concern; the FDA label warns explicitly against handling crushed or broken tablets.

Patients on Concurrent Antihypertensives or Vasodilators

Oral minoxidil causes systemic vasodilation. At doses of 2.5 mg to 5 mg daily, which Keeps prescribes for hair loss, clinically meaningful reductions in blood pressure can occur [5]. A patient already on amlodipine, lisinopril, or a beta-blocker may experience additive hypotension. This interaction requires a review of the full medication list and baseline blood pressure, neither of which Keeps reliably obtains via asynchronous intake.

Patient Profiles Who Should Avoid Cove (Migraine)

Cove prescribes triptans (sumatriptan, rizatriptan), gepants (rimegepant), topiramate, and propranolol for migraine prevention and acute treatment. The American Headache Society's 2021 consensus statement recommends that migraine diagnosis and treatment selection account for cardiovascular risk, medication-overuse history, and neurological red flags [6].

Patients With Cardiovascular or Cerebrovascular Disease

Triptans are serotonin 5-HT1B/1D receptor agonists that cause vasoconstriction. The FDA contraindications for sumatriptan include ischemic coronary artery disease, Prinzmetal's angina, history of stroke or TIA, peripheral vascular disease, and uncontrolled hypertension [7]. Cove's intake form asks about heart conditions, but the threshold for flagging and escalating borderline responses depends on the reviewing clinician's diligence and the quality of the patient's self-report. A patient with a recent abnormal stress test or undiagnosed angina may not know how to characterize their symptoms on a form.

Patients With Medication-Overuse Headache

The International Classification of Headache Disorders, 3rd edition, defines medication-overuse headache as headache occurring on 15 or more days per month in a patient using acute headache medications on 10 or more days per month for more than three months [8]. Prescribing additional triptans to a patient who already overuses them worsens the underlying condition. Identifying this pattern requires a detailed headache diary review and often a structured clinical interview, not a brief questionnaire.

Patients on Serotonergic Medications

Combining triptans with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) carries a theoretical risk of serotonin syndrome. The FDA issued an advisory on this interaction in 2006 [9]. Cove's intake asks about current medications, but the clinical significance of a specific combination requires active clinical judgment about dose, timing, and the patient's history of prior reactions.

Patients Needing Neurological Workup

New-onset headache in a patient over age 50, headache with thunderclap onset, or headache with associated neurological symptoms are red flags that require imaging and neurological evaluation before any migraine-specific treatment is started. The American Academy of Neurology guidelines specify these red-flag criteria [10]. Cove cannot perform fundoscopy, assess papilledema, or order emergent MRI.

Patient Profiles Who Should Avoid Facet (Dermatology)

Facet prescribes tretinoin, azelaic acid, niacinamide formulations, and hydroquinone for acne and hyperpigmentation. For mild-to-moderate comedonal or inflammatory acne in otherwise healthy adults, these agents are appropriate first-line options per American Academy of Dermatology guidelines [11]. The concern arises in specific populations.

Patients Who Are Pregnant or Planning Pregnancy

Tretinoin is a retinoid. Systemic retinoids (isotretinoin) are teratogenic at a level that requires the iPLEDGE REMS program. Topical tretinoin carries lower systemic absorption, but the FDA label advises avoiding use during pregnancy because adequate and well-controlled studies in pregnant women have not been conducted [12]. Facet's intake should screen for pregnancy, but asynchronous review limits the ability to counsel patients about contraception requirements and the risk window around conception.

Patients With Rosacea Misidentified as Acne

Tretinoin can exacerbate rosacea. Because facial flushing, papules, and pustules in rosacea can mimic acne vulgaris, a text-and-photo intake has meaningful error rates in distinguishing the two conditions. A 2020 retrospective audit in Dermatology and Therapy found that telemedicine acne consultations had a diagnostic concordance of approximately 74% with in-person dermatology assessments [13]. A 26% discordance rate is clinically significant when the wrong treatment actively worsens the condition.

Patient Profiles Who Should Avoid Lemonaid / Thirty Madison Sexual Health

Lemonaid Health, now integrated into the Thirty Madison portfolio, provides prescriptions for sildenafil and tadalafil for erectile dysfunction and hormonal contraception. The FDA-approved labeling for sildenafil (Viagra) lists absolute contraindications including concurrent use of nitrates in any form and concurrent use of riociguat [14].

Patients on Nitrates or Alpha-Blockers

Sildenafil combined with organic nitrates causes a potentially fatal synergistic drop in blood pressure. The interaction is absolute. Any patient using nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or amyl nitrite in any form must not use sildenafil or tadalafil. Alpha-blockers also potentiate hypotension when combined with PDE-5 inhibitors, and the FDA label recommends dose adjustment or avoidance [14]. An asynchronous intake form that asks "do you take nitrates" relies entirely on the patient knowing what a nitrate is. This gap is a documented reason why the American Urological Association recommends a structured cardiovascular risk assessment before initiating PDE-5 inhibitor therapy [15].

Patients With Uncontrolled Hypertension or Recent Cardiac Events

The Princeton Consensus III guidelines recommend that patients with a resting systolic blood pressure above 170 mmHg, uncontrolled hypertension, high-risk arrhythmias, or a cardiac event within the preceding two to six weeks be evaluated by a cardiologist before PDE-5 inhibitor use [16].

Is Thirty Madison Legit? Regulatory Standing and Complaint Data

Thirty Madison's sub-brands are operated by licensed medical professionals, use FDA-approved medications, and are structured as legitimate telehealth practices under applicable state laws. This is not the same as saying the platform is appropriate for every patient who self-selects into it.

LegitScript and Pharmacy Accreditation Status

LegitScript is a third-party verification organization that the FDA and major payment processors use to assess the legitimacy of online pharmacies and telehealth platforms. As of publicly available 2024 LegitScript records, Thirty Madison's consumer-facing brands do not appear on the LegitScript-certified telehealth provider list [17]. LegitScript certification is not legally required, but its absence means one independent layer of pharmacy-practice verification is not in place.

BBB Complaint History

The Better Business Bureau profile for Thirty Madison shows a pattern of complaints related to billing disputes, difficulty canceling subscriptions, and charges after cancellation requests. As of January 2025, Thirty Madison is not BBB-accredited [18]. The complaint categories (billing and subscription practices) do not directly reflect prescribing safety but do indicate gaps in the administrative and consent processes that can affect whether patients receive accurate information about ongoing charges tied to medication refills.

FDA Warning Letters and State Board Actions

A search of the FDA Warning Letter database through January 2025 does not return an active warning letter specifically addressed to Thirty Madison or its sub-brands [19]. The absence of a warning letter is not a safety endorsement. The FDA does not audit every telehealth provider. State medical board records for individual prescribers require state-by-state searches.

When a Higher-Acuity Setting Is the Right Choice

Several clinical situations put a patient outside the appropriate scope of a D2C telehealth platform regardless of the specific brand.

Multi-System Disease or Complex Polypharmacy

A patient managing type 2 diabetes, hypertension, and chronic kidney disease on five or more daily medications needs a primary care physician or specialist who can review the full interaction profile before adding any new agent. Finasteride, oral minoxidil, and triptans all have interaction profiles that change meaningfully in the context of impaired renal or hepatic clearance [2] [7].

Diagnostic Uncertainty

The telehealth model assumes the diagnosis is already established or can be established by photo and questionnaire. When the diagnosis is uncertain, the appropriate first step is an in-person evaluation. Hair loss that could reflect thyroid disease, iron deficiency, or lupus requires laboratory testing before assuming androgenetic alopecia [20]. Headache that could reflect intracranial hypertension requires neuroimaging before assuming migraine.

Pediatric and Adolescent Patients

None of the Thirty Madison brands are indicated or approved for patients under age 18 in most of their product lines. Finasteride is not approved for use in pediatric patients. Pediatric migraine management requires specialist oversight per American Academy of Pediatrics guidance [21].

Patients With Prior Adverse Drug Reactions to the Same Drug Class

A patient who experienced post-finasteride syndrome symptoms (persistent sexual dysfunction, depression, cognitive complaints) after a prior finasteride trial is not a candidate for re-initiation via an asynchronous telehealth platform. The same logic applies to a patient with a prior triptan-related chest pain event or a prior severe vasodilator reaction to minoxidil.

A Decision Framework for Evaluating Whether Thirty Madison Is Appropriate

Patients considering any Thirty Madison brand can use the following questions as a preliminary screen. A "yes" to any single question is a signal to pursue an in-person evaluation instead.

1. Do you have a cardiovascular diagnosis, a prior cardiac event, or an abnormal stress test within the past two years?
2. Are you taking five or more prescription medications daily?
3. Do you have impaired kidney function (eGFR <60 mL/min/1.73m2) or liver disease?
4. Are you pregnant, trying to conceive, or breastfeeding?
5. Has your primary care physician or specialist explicitly told you that a new medication requires close monitoring?
6. Is your diagnosis uncertain, or has a prior physician expressed uncertainty about your diagnosis?
7. Do you have a history of an adverse reaction to any drug in the same class as the one you are considering?

A "no" to all seven does not guarantee safety. It does mean the risk profile is lower and the D2C model is less likely to miss a contraindication.